Spago Nanomedical AB

Equities

SPAG

SE0004899474

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 10:42:26 2024-04-26 am EDT			5-day change	1st Jan Change
0.36 ^SEK	+0.56%		+8.76%	+10.09%

Apr. 24	Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad	CI
Apr. 16	Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024	CI

Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa

October 23, 2023 at 02:46 am EDT

Spago Nanomedical has achieved a significant milestone in its cancer therapy development journey. The company's drug candidate, 177Lu-SN201, has received approval to initiate the clinical phase I/IIa study, Tumorad-01, in Australia.

Latest news about Spago Nanomedical AB

Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad	Apr. 24	CI
Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024	Apr. 16	CI
Spago Nanomedical AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 07	CI
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 07	CI
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01	Jan. 10	CI
Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis	Dec. 20	CI
Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 in Patients with Endometriosis	Dec. 15	CI
Spago Nanomedical AB Announces First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIA Study Within the Tumorad(R) Program	Dec. 07	CI
Spago Nanomedical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Spago Nanomedical AB Announces Publication of Four New Patent Applications Filed with the European Patent Office	23-10-24	CI
Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa	23-10-23	CI
Spago Nanomedical AB Receives Approval to Initiate the Clinical Phase I/IIa Study with Tumorad in Australia	23-10-19	CI
Spago Nanomedical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02	23-06-28	CI
Spago Nanomedical AB Announces Establishment of A Scientific Advisory Board	23-06-13	CI
Spago Nanomedical AB Submits Application to Start Tumorad(R) Clinical Phase I/IIa Study	23-05-23	CI
Spago Nanomedical AB Elects New Directors	23-05-10	CI
Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Spago Nanomedical AB Announces Board Resignations	23-04-05	CI
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-02	CI
Spago Nanomedical AB Publishes Scientific Paper on Positive Preclinical Data with Tumorad(R) as Treatment of Solid Tumors	23-01-10	CI
First Patient Dosed in Spago Nanomedical’S Endometriosis Phase Iia Clinical Study	22-12-08	CI
Spago Nanomedical Initiates Clinical Trial with Spagopix in Endometriosis and Concludes SpagoPix -01	22-12-06	CI
Spago Nanomedical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Spago Nanomedical Gets SpagoPix Abstract Accepted At Breast Cancer Conference	22-09-21	CI

Chart Spago Nanomedical AB

Duration

Period

More charts

Company Profile

Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with radionuclides for selective treatment of cancers, which are unsuitable for surgery or external radiation; and Archaea Platin, aimed at delivering of chemotherapeutic substance cisplatin selectively to tumors in order to reduce side effects on healthy tissue. The Company's technology comprises a technology platform IonXgel, which is a nano-sized biocompatible material consisting of polar polymers; a protein-based drug delivery platform, ProtRc; and 3PEG, a platform which enables attachment of polyethylene glycol (PEG) derivatives to small molecules (PEGylation).

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Spago Nanomedical AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
SPAGO NANOMEDICAL AB	+10.09%	7.38M
EXACT SCIENCES CORPORATION	-20.45%	10.82B
IOVANCE BIOTHERAPEUTICS, INC.	+43.17%	3.25B
GUARDANT HEALTH, INC.	-35.86%	2.11B
BGI GENOMICS CO., LTD.	-17.21%	2.08B
VERACYTE, INC.	-29.81%	1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.56%	1.02B
SEEGENE, INC.	-4.37%	733M
CAREDX, INC	-37.00%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	377M

Bio Diagnostics & Testing